These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Dumas JA; Newhouse PA Pharmacol Biochem Behav; 2011 Aug; 99(2):254-61. PubMed ID: 21382398 [TBL] [Abstract][Full Text] [Related]
26. Enhancing cognition through pharmacological and environmental interventions: Examples from preclinical models of neurodevelopmental disorders. Morè L; Lauterborn JC; Papaleo F; Brambilla R Neurosci Biobehav Rev; 2020 Mar; 110():28-45. PubMed ID: 30981451 [TBL] [Abstract][Full Text] [Related]
27. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014. Froestl W; Muhs A; Pfeifer A J Alzheimers Dis; 2014; 42(1):1-68. PubMed ID: 24903780 [TBL] [Abstract][Full Text] [Related]
28. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Araujo JA; Studzinski CM; Milgram NW Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):411-22. PubMed ID: 15795050 [TBL] [Abstract][Full Text] [Related]
29. The impact of drugs against dementia on cognition in aging and mild cognitive impairment. Ihl R Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S38-43. PubMed ID: 13130387 [TBL] [Abstract][Full Text] [Related]
30. Strategies for preservation of memory function in patients with brain metastases. Dye NB; Gondi V; Mehta MP Chin Clin Oncol; 2015 Jun; 4(2):24. PubMed ID: 26112810 [TBL] [Abstract][Full Text] [Related]
31. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Bernick C; Katz R; Smith NL; Rapp S; Bhadelia R; Carlson M; Kuller L; Neurology; 2005 Nov; 65(9):1388-94. PubMed ID: 16275825 [TBL] [Abstract][Full Text] [Related]
32. Cognition as a target in major depression: new developments. Solé B; Jiménez E; Martinez-Aran A; Vieta E Eur Neuropsychopharmacol; 2015 Feb; 25(2):231-47. PubMed ID: 25640673 [TBL] [Abstract][Full Text] [Related]
33. The use of cognitive enhancers in animal models of fear extinction. Kaplan GB; Moore KA Pharmacol Biochem Behav; 2011 Aug; 99(2):217-28. PubMed ID: 21256147 [TBL] [Abstract][Full Text] [Related]
34. Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial. Doraiswamy PM; Babyak MA; Hennig T; Trivedi R; White WD; Mathew JP; Newman MF; Blumenthal JA Psychopharmacol Bull; 2007; 40(2):54-62. PubMed ID: 17514186 [TBL] [Abstract][Full Text] [Related]
35. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. Froestl W; Muhs A; Pfeifer A J Alzheimers Dis; 2012; 32(4):793-887. PubMed ID: 22886028 [TBL] [Abstract][Full Text] [Related]
36. Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study. Bruce J; Hancock L; Roberg B; Brown A; Henkelman E; Lynch S Cogn Behav Neurol; 2012 Sep; 25(3):107-14. PubMed ID: 22960434 [TBL] [Abstract][Full Text] [Related]
37. Methods for delivering and evaluating the efficacy of cognitive enhancement. Harvey PD; Keefe RS Handb Exp Pharmacol; 2015; 228():5-25. PubMed ID: 25977078 [TBL] [Abstract][Full Text] [Related]